JP5426671B2 - Ｃ型肝炎ウイルス阻害剤として有用な大環状インドール誘導体 - Google Patents
Ｃ型肝炎ウイルス阻害剤として有用な大環状インドール誘導体 Download PDFInfo
- Publication number
- JP5426671B2 JP5426671B2 JP2011517026A JP2011517026A JP5426671B2 JP 5426671 B2 JP5426671 B2 JP 5426671B2 JP 2011517026 A JP2011517026 A JP 2011517026A JP 2011517026 A JP2011517026 A JP 2011517026A JP 5426671 B2 JP5426671 B2 JP 5426671B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- methyl
- compounds
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CN(CCN(CI)CCN(*)SNC(c(cc1)cc2c1c(*)c-1[n]2CC2=C(*)c3c-1ccc(*)c3)=O)C2=O Chemical compound CN(CCN(CI)CCN(*)SNC(c(cc1)cc2c1c(*)c-1[n]2CC2=C(*)c3c-1ccc(*)c3)=O)C2=O 0.000 description 12
- ARQOXSUDMMENRI-UHFFFAOYSA-N C/C=S(/NC(c1ccc(c(C2CCCCC2)c-2[n]3CC4=Cc5c-2ccc(OC)c5)c3c1)=O)\N(C)CCOCCN(C)C4=O Chemical compound C/C=S(/NC(c1ccc(c(C2CCCCC2)c-2[n]3CC4=Cc5c-2ccc(OC)c5)c3c1)=O)\N(C)CCOCCN(C)C4=O ARQOXSUDMMENRI-UHFFFAOYSA-N 0.000 description 1
- BFHBKNBAEGVCRH-WBBHLRKXSA-N CC(C)(C)OC(c1ccc(c(C2CCCCC2)c(-c(cc2)c([C@H]3C4)cc2OC)[n]2C[C@@]34C(O)=O)c2c1)=O Chemical compound CC(C)(C)OC(c1ccc(c(C2CCCCC2)c(-c(cc2)c([C@H]3C4)cc2OC)[n]2C[C@@]34C(O)=O)c2c1)=O BFHBKNBAEGVCRH-WBBHLRKXSA-N 0.000 description 1
- HLMLFHFYBOKBMW-UHFFFAOYSA-N CC(C)(C)OC(c1ccc(c(C2CCCCC2)c-2[n]3CC(C(N(C)CCOCCN(C)S(N)(=O)=O)O)=Cc4c-2ccc(OC)c4)c3c1)=O Chemical compound CC(C)(C)OC(c1ccc(c(C2CCCCC2)c-2[n]3CC(C(N(C)CCOCCN(C)S(N)(=O)=O)O)=Cc4c-2ccc(OC)c4)c3c1)=O HLMLFHFYBOKBMW-UHFFFAOYSA-N 0.000 description 1
- PMBODYVAUIAWFA-UOSBZTQKSA-N CC(C)CC(C)(C)Oc(cc1)cc2c1c(C1CCCCC1)c(-c(cc1)c([C@H]3C4)cc1OC)[n]2C[C@@]34C(N(C)CCOCCNC)=O Chemical compound CC(C)CC(C)(C)Oc(cc1)cc2c1c(C1CCCCC1)c(-c(cc1)c([C@H]3C4)cc1OC)[n]2C[C@@]34C(N(C)CCOCCNC)=O PMBODYVAUIAWFA-UOSBZTQKSA-N 0.000 description 1
- AYJNQEQVFRXELH-UHFFFAOYSA-N CC(C)N(CCCCN(C)C(OC(C)(C)C)=O)S(N)(=O)=O Chemical compound CC(C)N(CCCCN(C)C(OC(C)(C)C)=O)S(N)(=O)=O AYJNQEQVFRXELH-UHFFFAOYSA-N 0.000 description 1
- RATHQSJOYAVCIL-UHFFFAOYSA-N CCCN(CCNC(C1(C2)C2c(cc(cc2)OC)c2-c2c(C3CCCCC3)c(ccc(C(N3)=O)c4)c4[N-]2C1)=O)CCN(C)S3(=O)=O Chemical compound CCCN(CCNC(C1(C2)C2c(cc(cc2)OC)c2-c2c(C3CCCCC3)c(ccc(C(N3)=O)c4)c4[N-]2C1)=O)CCN(C)S3(=O)=O RATHQSJOYAVCIL-UHFFFAOYSA-N 0.000 description 1
- LGCASHFRGKGTHN-DMWKKASYSA-N CN(CCCC/C=N\C(C(C[n]1c2c3)=CC(CCC(Cl)=C4)=C4c1c(C1CCCCC1)c2ccc3C(N1)=O)=O)S1(=O)=O Chemical compound CN(CCCC/C=N\C(C(C[n]1c2c3)=CC(CCC(Cl)=C4)=C4c1c(C1CCCCC1)c2ccc3C(N1)=O)=O)S1(=O)=O LGCASHFRGKGTHN-DMWKKASYSA-N 0.000 description 1
- DNGANABSIGDMEF-RSOIKELASA-M CN(CCOCCN(C)[Os](NC(c1ccc(c(C2CCCCC2)c-2[n]3C[C@]4(C5)[C@H]5c5c-2ccc(OC)c5)c3c1)=O)[Os]C)C4=O Chemical compound CN(CCOCCN(C)[Os](NC(c1ccc(c(C2CCCCC2)c-2[n]3C[C@]4(C5)[C@H]5c5c-2ccc(OC)c5)c3c1)=O)[Os]C)C4=O DNGANABSIGDMEF-RSOIKELASA-M 0.000 description 1
- CJZYFXLJFNDALI-UHFFFAOYSA-N NC1=CC=CCC1 Chemical compound NC1=CC=CCC1 CJZYFXLJFNDALI-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N OC(C(F)(F)F)=O Chemical compound OC(C(F)(F)F)=O DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08159965 | 2008-07-08 | ||
| EP08159965.6 | 2008-07-08 | ||
| EP08160254.2 | 2008-07-11 | ||
| EP08160254 | 2008-07-11 | ||
| EP08161743 | 2008-08-04 | ||
| EP08161743.3 | 2008-08-04 | ||
| PCT/EP2009/004942 WO2010003658A1 (en) | 2008-07-08 | 2009-07-08 | Macrocyclic indole derivatives useful as hepatitis c virus inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013176771A Division JP5808370B2 (ja) | 2008-07-08 | 2013-08-28 | Ｃ型肝炎ウイルス阻害剤として有用な大環状インドール誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011527299A JP2011527299A (ja) | 2011-10-27 |
| JP2011527299A5 JP2011527299A5 (enExample) | 2013-10-17 |
| JP5426671B2 true JP5426671B2 (ja) | 2014-02-26 |
Family
ID=40972916
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517026A Expired - Fee Related JP5426671B2 (ja) | 2008-07-08 | 2009-07-08 | Ｃ型肝炎ウイルス阻害剤として有用な大環状インドール誘導体 |
| JP2013176771A Active JP5808370B2 (ja) | 2008-07-08 | 2013-08-28 | Ｃ型肝炎ウイルス阻害剤として有用な大環状インドール誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013176771A Active JP5808370B2 (ja) | 2008-07-08 | 2013-08-28 | Ｃ型肝炎ウイルス阻害剤として有用な大環状インドール誘導体 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8921355B2 (enExample) |
| EP (1) | EP2310396B1 (enExample) |
| JP (2) | JP5426671B2 (enExample) |
| KR (1) | KR101640374B1 (enExample) |
| CN (1) | CN102089314B (enExample) |
| AP (1) | AP2743A (enExample) |
| AR (1) | AR072726A1 (enExample) |
| AU (1) | AU2009267389B8 (enExample) |
| BR (1) | BRPI0915887B8 (enExample) |
| CA (1) | CA2729307C (enExample) |
| CL (1) | CL2011000032A1 (enExample) |
| CO (1) | CO6351793A2 (enExample) |
| CR (1) | CR20110076A (enExample) |
| DK (1) | DK2310396T3 (enExample) |
| EA (1) | EA019008B1 (enExample) |
| EC (1) | ECSP11010750A (enExample) |
| ES (1) | ES2651038T3 (enExample) |
| HN (1) | HN2011000072A (enExample) |
| HR (1) | HRP20171892T1 (enExample) |
| HU (1) | HUE035244T2 (enExample) |
| IL (1) | IL210086A (enExample) |
| LT (1) | LT2310396T (enExample) |
| MX (1) | MX2011000276A (enExample) |
| NI (1) | NI201100010A (enExample) |
| NO (1) | NO2310396T3 (enExample) |
| NZ (2) | NZ590073A (enExample) |
| SI (1) | SI2310396T1 (enExample) |
| SV (1) | SV2011003796A (enExample) |
| TW (1) | TWI454476B (enExample) |
| UY (1) | UY31973A (enExample) |
| WO (1) | WO2010003658A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008339917B2 (en) | 2007-12-24 | 2013-02-07 | Tibotec Pharmaceuticals | Macrocyclic indoles as hepatitis C virus inhibitors |
| TWI454476B (zh) * | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| UA108211C2 (uk) * | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| US20130028865A1 (en) * | 2010-04-13 | 2013-01-31 | Medivir Ab | Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside |
| US9127010B2 (en) | 2010-06-24 | 2015-09-08 | Janssen Sciences Ireland Uc | Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid |
| ES2655942T3 (es) | 2011-09-02 | 2018-02-22 | Novartis Ag | Sal de colina de un compuesto anti-inflamatorio de ciclobutenodiona sustituida |
| US8716275B2 (en) * | 2011-10-20 | 2014-05-06 | Bristol-Myers Squibb Company | Compound for the treatment of hepatitis C |
| MX2015002684A (es) | 2012-08-31 | 2015-05-12 | Janssen Pharmaceuticals Inc | Combinacion de un inhibidor macrociclico de proteasas del vhc, un inhibidor del vhc no nucleosidico y ritonavir. |
| WO2014152275A1 (en) * | 2013-03-14 | 2014-09-25 | Concert Pharmaceuticals, Inc. | Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055 |
| US10450263B2 (en) | 2017-02-10 | 2019-10-22 | Southern Research Institute | Benzo annulenes as antiviral agents |
| KR101974388B1 (ko) | 2017-06-23 | 2019-05-02 | (주)에니켐텍 | 알킬 디에틸렌 트리아민 유도체 및 이의 제조방법 |
| US11066357B2 (en) | 2017-12-26 | 2021-07-20 | Southern Research Institute | Benzoannulene derivatives as antiviral agents |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| US12060148B2 (en) | 2022-08-16 | 2024-08-13 | Honeywell International Inc. | Ground resonance detection and warning system and method |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US6054472A (en) * | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| US5807876A (en) * | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US20050267836A1 (en) * | 1996-03-25 | 2005-12-01 | Cfph, Llc | Method and system for transacting with a trading application |
| AU723730B2 (en) | 1996-04-23 | 2000-09-07 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of IMPDH enzyme |
| DE69816280T2 (de) | 1997-03-14 | 2004-05-27 | Vertex Pharmaceuticals Inc., Cambridge | Inhibitoren des impdh-enzyms |
| EE200100492A (et) | 1999-03-19 | 2002-12-16 | Vertex Pharmaceuticals Incorporated | Ensüümi IMPDH inhibiitorid |
| JP4778665B2 (ja) | 2000-08-30 | 2011-09-21 | パナソニック株式会社 | プラズマディスプレイ表示装置の製造方法 |
| UA84050C2 (en) | 2004-01-30 | 2008-09-10 | Медивир Аб | Hcv ns-3-serine protease inhibitors |
| US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| AU2006286441A1 (en) | 2005-09-02 | 2007-03-08 | Janssen R&D Ireland | Benzodiazepines as HCV inhibitors |
| US7399758B2 (en) * | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| GB0522881D0 (en) | 2005-11-10 | 2005-12-21 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2007092000A1 (en) | 2006-02-06 | 2007-08-16 | Bristol-Myers Squibb Company | Inhibitors of hcv replication |
| US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) * | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521442B2 (en) * | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| DE602007011658D1 (de) | 2006-10-10 | 2011-02-10 | Medivir Ab | Hcv-nukleosidinhibitor |
| JP2010513450A (ja) | 2006-12-20 | 2010-04-30 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | 抗ウイルス性インドール |
| CN101754970B (zh) * | 2007-07-17 | 2013-07-10 | P.安杰莱蒂分子生物学研究所 | 用于治疗丙型肝炎的大环吲哚衍生物 |
| TWI454476B (zh) * | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| TW201023858A (en) | 2008-09-18 | 2010-07-01 | Ortho Mcneil Janssen Pharm | Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside |
| SG173772A1 (en) | 2009-02-27 | 2011-09-29 | Ortho Mcneil Janssen Pharm | Amorphous salt of a macrocyclic inhibitor of hcv |
| US20130028865A1 (en) | 2010-04-13 | 2013-01-31 | Medivir Ab | Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside |
| US9127010B2 (en) | 2010-06-24 | 2015-09-08 | Janssen Sciences Ireland Uc | Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid |
| MX2015002684A (es) | 2012-08-31 | 2015-05-12 | Janssen Pharmaceuticals Inc | Combinacion de un inhibidor macrociclico de proteasas del vhc, un inhibidor del vhc no nucleosidico y ritonavir. |
-
2009
- 2009-07-07 TW TW098122947A patent/TWI454476B/zh not_active IP Right Cessation
- 2009-07-08 AU AU2009267389A patent/AU2009267389B8/en not_active Ceased
- 2009-07-08 LT LTEP09793887.2T patent/LT2310396T/lt unknown
- 2009-07-08 ES ES09793887.2T patent/ES2651038T3/es active Active
- 2009-07-08 MX MX2011000276A patent/MX2011000276A/es active IP Right Grant
- 2009-07-08 SI SI200931765T patent/SI2310396T1/en unknown
- 2009-07-08 US US13/000,583 patent/US8921355B2/en active Active
- 2009-07-08 WO PCT/EP2009/004942 patent/WO2010003658A1/en not_active Ceased
- 2009-07-08 HU HUE09793887A patent/HUE035244T2/hu unknown
- 2009-07-08 EP EP09793887.2A patent/EP2310396B1/en active Active
- 2009-07-08 AR ARP090102596A patent/AR072726A1/es unknown
- 2009-07-08 BR BRPI0915887A patent/BRPI0915887B8/pt active IP Right Grant
- 2009-07-08 KR KR1020117002865A patent/KR101640374B1/ko not_active Expired - Fee Related
- 2009-07-08 JP JP2011517026A patent/JP5426671B2/ja not_active Expired - Fee Related
- 2009-07-08 CA CA2729307A patent/CA2729307C/en active Active
- 2009-07-08 HR HRP20171892TT patent/HRP20171892T1/hr unknown
- 2009-07-08 CN CN200980127068.3A patent/CN102089314B/zh active Active
- 2009-07-08 EA EA201170153A patent/EA019008B1/ru not_active IP Right Cessation
- 2009-07-08 DK DK09793887.2T patent/DK2310396T3/en active
- 2009-07-08 NZ NZ590073A patent/NZ590073A/xx not_active IP Right Cessation
- 2009-07-08 NZ NZ603343A patent/NZ603343A/xx not_active IP Right Cessation
- 2009-07-08 UY UY0001031973A patent/UY31973A/es unknown
- 2009-07-08 NO NO09793887A patent/NO2310396T3/no unknown
- 2009-07-08 AP AP2010005521A patent/AP2743A/xx active
-
2010
- 2010-12-19 IL IL210086A patent/IL210086A/en not_active IP Right Cessation
- 2010-12-21 CO CO10160463A patent/CO6351793A2/es active IP Right Grant
-
2011
- 2011-01-06 NI NI2011000101A patent/NI201100010A/es unknown
- 2011-01-07 HN HN2011000072A patent/HN2011000072A/es unknown
- 2011-01-07 SV SV2011003796A patent/SV2011003796A/es unknown
- 2011-01-07 EC EC2011010750A patent/ECSP11010750A/es unknown
- 2011-01-07 CL CL2011000032A patent/CL2011000032A1/es unknown
- 2011-02-08 CR CR20110076A patent/CR20110076A/es unknown
-
2013
- 2013-03-15 US US13/836,168 patent/US9427440B2/en active Active
- 2013-08-28 JP JP2013176771A patent/JP5808370B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5808370B2 (ja) | Ｃ型肝炎ウイルス阻害剤として有用な大環状インドール誘導体 | |
| CA2710644C (en) | Macrocyclic indoles as hepatitis c virus inhibitors | |
| AU2009281138B2 (en) | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | |
| AU2013204963B2 (en) | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | |
| HK1155734B (en) | Macrocyclic indole derivatives useful as hepatitis c virus inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120706 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130828 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20130828 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20130920 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131008 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131029 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131128 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5426671 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |